Contact Us
Subscribe
e-Edition

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

14°
- Middle Point, OH (45863)
  Today
  
  Clear skies. Low 8F. Winds ESE at 5 to 10 mph..
  
  Tonight
  
  Clear skies. Low 8F. Winds ESE at 5 to 10 mph.
  
  Updated: February 8, 2026 @ 8:16 pm
- Full Forecast

Site search

Home
News
- Local News
Sports
Obituaries
Local Events
Photos
e-Edition
Classifieds

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

MaxCyte, Inc. - Common Stock (NQ:MXCT)

0.8080 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EST, Feb 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about MaxCyte, Inc. - Common Stock

< Previous 1 2 3 Next >

MaxCyte Reports Second Quarter and Half-Year 2024 Financial Results and Updates Full Year 2024 Guidance

August 06, 2024

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024

July 09, 2024

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte to Participate in William Blair 44th Annual Growth Stock Conference

May 29, 2024

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and Development

May 22, 2024

Legend Biotech obtains license to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its non-viral engineered pipeline portfolio across a variety of cell types including T...

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Reports First Quarter 2024 Financial Results and Updates 2024 Guidance

May 07, 2024

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte to Report First Quarter 2024 Financial Results on May 7, 2024

April 10, 2024

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

April 02, 2024

Be Biopharma to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform within its Engineered B Cell Medicines programs

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

March 12, 2024

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

March 04, 2024

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

February 09, 2024

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

January 30, 2024

Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancers

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

January 23, 2024

Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood cancer...

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results

January 08, 2024

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

January 03, 2024

Lion TCR to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to develop and scale TCR-T cell therapies for solid tumors and viral-related diseases.

From MaxCyte, Inc; Lion TCR

Via GlobeNewswire

MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

January 02, 2024

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023

December 11, 2023

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member

November 16, 2023

MaxCyte continues supporting the advancement of novel therapeutics and looks to support education and advancement of mRNA medicines

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance

November 08, 2023

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte to Participate in Two Upcoming Investor Conferences

November 06, 2023

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance

October 04, 2023

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

September 06, 2023

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte to Participate in Baird Global Healthcare Conference

September 05, 2023

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance

August 09, 2023

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients

August 01, 2023

Prime Medicine to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to advance their innovative Prime Editing technology and develop a new class of one-time, potentially curative...

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023

July 13, 2023

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte and Vittoria Biotherapeutics Sign Strategic Platform License to Advance Next Generation Cellular Therapies

July 10, 2023

MaxCyte’s Flow Electroporation® technology and ExPERT™ platform will support Vittoria’s Senza5™ technology to enhance efficacy and improve clinical utility of T-cell therapies.

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Signs Strategic Platform License with Lyell Immunopharma

July 06, 2023

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte to Participate in Upcoming Investor Conferences

June 01, 2023

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Reports First Quarter 2023 Financial Results and Updates Full Year 2023 Guidance

May 10, 2023

From MaxCyte, Inc

Via GlobeNewswire

MaxCyte Signs Strategic Platform License with Walking Fish Therapeutics to Support the Development of its Innovative B Cell Platform

May 04, 2023

Walking Fish to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to engineer novel B-cell based medicines for the treatment of serious diseases

From MaxCyte, Inc

Via GlobeNewswire

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Announcements
Sports
Entertainment
Local Events
Obituaries
Photos
Videos
Online Features

Services

Subscription Services
Submission Forms
Classifieds
Place an Ad
Promote Your Event
Email Alerts
Search
Weather

minstercommunitypost.com
PO Box 155
Minster, OH 45863
Phone: 419-300-1076
Email: editor@minstercommunitypost.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Middle Point, OH (45863)

Today

Tonight

MaxCyte, Inc. - Common Stock (NQ:MXCT)

Press Releases about MaxCyte, Inc. - Common Stock

Sections

Services